Acquisition leverage Position resilience-backed capabilities from the Ology Bioservices lineage to cross-sell full development, manufacturing, and cGMP services to existing DoD and NIH contract customers that previously engaged Ology or now rely on Resilience for expanded capacity.

Blue Ash expansion Capitalize on Resilience’ expansion plans in Ohio to target regional biopharma manufacturers seeking scalable manufacturing, fill-finish, and high-containment (BSL-3) capabilities aligned with Ology’s legacy platform technologies.

Platform integration Highlight opportunity to integrate proprietary platform technologies for biologics production into customer pipelines, offering end-to-end solutions from preclinical to commercial production to reduce development timelines.

Strategic partnerships Engage with large pharma and government-facing entities already collaborating with Resilience (for example Lilly partnerships) to broaden contracts around capacity expansion, accelerated manufacturing, and multi-site production networks.

SMB to mid-market Target mid-sized biotechs seeking cGMP manufacturing and development support who could benefit from Resilience’ growing footprint in Ohio and nationwide, leveraging cost efficiencies from scale and integrated services.